Cardio-Oncology Registry

Study Overview
=================
Brief Summary
-----------------
Cardio-oncology is an emerging field. Most of the data available have been issued from either retrospective analysis, industry data or pharmacovigilance data. These data sources include a number of bias. CONFUCIUS is a single tertiary centre prospective registry including all patients who have been referred for cardio-oncology assessemnt. The objectives are to provide a comprehensive vue of cardoi-oncology, enable to detect early signals of cardiotoxicity and enhance ancillary projetcts aiming at specific populations (e.g., type of cancer) and/or drugs.

Official Title
-----------------
Cardio-Oncologie: étude Pilote évaluant la faisabilité, Utilité Concrète, Interdisciplinaire d'Une Unité Spécialisée

Conditions
-----------------
Arrhythmia, Cancer, Cardiac Disease, Metabolic Syndrome, Heart Diseases

Intervention / Treatment
-----------------
* Other: No interventions are planned


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: referred to cardio-oncology Exclusion Criteria: refusal to participate

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: No interventions are planned|Non applicable|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of cardio-toxicty | Number of patients with cardiotoxicity in a cohort of patients referred to a cardio-oncology clinic | 5 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Metabolic | Correlation between oncology treatments, cardiovascular therapies, behaviour therapies and the number of patients with metabolic disorders (diabetes or dyslipidemia). | 5 years | 
| Analysis of cardiotoxicity | Correlation of cardio-toxicity overall, and in predefined subgroups; statistical associatoin with outcomes. | 5 years | 
| Analysis of cardioprotective strategies | Correlation between the use of cardiovascular drugs and the number of patients with cardiotoxicity. | 5 years | 
| Analysis of underlying cardiovacsular profile | Correlation between underlying cardioascular profile and the number of patients with cardiotoxicity. | 5 years | 
| Analysis of arrhythmias | Correlation between incident arrhythmias and cancer drugs | 5 years | 
| Precision medicine | Correlation between biomarkers with use of artificial intelligence and the number of patients with cardiotoxicity. | 5 years | 
| Oncology | Adherence to oncology treatment plan as stated in the multidisciplinary team meeting in patients with cardio-oncology assessment compared to matched patients with no cardio-oncology assessment within our institution; outcomes. | 5 years | 
| Cardiovascular outcomes | Assess cardiovascular outcomes (cardiovascular death, admission for heart failure, acute coronary syndrome, stroke). | 10 years | 
| Any advserse event | Correlation between any adverse event, oncology treatment, and outcomes. | 5 years | 
| Behaviour | Correlation of any behaviour treatment (exercice, rehabilitation, nutrition consultation) and the number of patents with cardiotoxocity. | 5 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
cancer, heart, cardiovascular, cardio-oncology, onco-cardiology, phamacology, precision medicine